Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Cervarix Offers “Excellent Protection”for Japanese Women As Well: Prof. Konno
May 24, 2010
- Takeda: Sales Down 4.7% Due to Patent Expiration for Lansoprazole in the US
May 24, 2010
- Kissei to Launch Japan's 1st EPO Biosimilar
May 24, 2010
- Astellas to Acquire OSI Pharmaceuticals
May 24, 2010
- Major New Entrants in Generics Market, Emergence of AGs (1)
May 24, 2010
- Astellas: Profits Down >25% Due to Patent Expiration for Prograf
May 24, 2010
- Major New Entrants in Generics Market, Emergence of AGs (2)
May 24, 2010
- Daiichi Sankyo: Sales Up 13.1% Driven by Olmesartan, Ranbaxy
May 24, 2010
- 3 Medical Devices Recommended for Approval
May 24, 2010
- Eisai: Aricept, Cancer-Related Products Drive Sales Up 2.7%
May 24, 2010
- Taiyo Yakuhin Recalls Another Product
May 24, 2010
- Korosho, METI Set Up Joint Task Force to Promote New Growth Strategy
May 17, 2010
- Collategene Achieves Primary Endpoint in PIII Trial: AnGes MG
May 17, 2010
- PMDA Should Continue, Even Expand Its Activities: Screening by GRU
May 17, 2010
- Asahi Kasei's AT-877 Fails to Meet Primary Endpoint in PIII
May 17, 2010
- PMDA to Relax Working Regulations for Former Company Employees
May 17, 2010
- Hisamitsu's HKT-500 Fails to Meet Primary Endpoint in PIII
May 17, 2010
- Five NIBIO Projects Screened by GRU
May 17, 2010
- NIBIO Identifies Protein Related to Colon, Esophageal Cancer
May 17, 2010
- BI Expects 1st Approval for Dabigatran for SPAF in Late 2010
May 17, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…